Novo Nordisk, a Danish multinational pharmaceutical company, agreed to acquire Forma Therapeutics, a clinical-stage biopharmaceutical company focused on transforming the lives of patients with sickle cell disease and rare blood disorders, for $1.1bn. "Today’s announcement is an exciting milestone that accelerates Forma’s purpose to transform the lives of patients with sickle cell disease and other serious hematological diseases. Novo Nordisk will partner closely with the sickle cell community to amplify our impact for patients around the world who urgently need new treatment options. We look forward to working together with Novo Nordisk to serve as a trusted partner to our communities and to advance innovation, access and health equity for patients," Frank D. Lee, Forma President and CEO.